Aspirin in the primary prevention of cardiovascular disease on diabetic patients: Systematic review and meta-analysis
• Aspirin modestly reduces major adverse cardiovascular events risk. • Aspirin does not reduce all-cause mortality risk. • Aspirin does increase the risk of major bleeding risk. • Aspirin prescription in primary prevention in diabetics must be individualized.
| Veröffentlicht in: | A pilot randomized controlled trial examining the feasibility, acceptability, and efficacy of Adapted Motivational Interviewing for post-operative bariatric surgery patients. - 2016. - Amsterdam [u.a.] |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , , , |
| Format: | Online-Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
2020
|
| Zugriff auf das übergeordnete Werk: | A pilot randomized controlled trial examining the feasibility, acceptability, and efficacy of Adapted Motivational Interviewing for post-operative bariatric surgery patients |
| Schlagworte: | Net clinical benefit Antiplatelet Primary prevention Diabetes mellitus Peripheral arterial disease Cardiovascular disease Coronary disease Cerebrovascular disease Revascularization |
| Umfang: | 9 |
| Zusammenfassung: | • Aspirin modestly reduces major adverse cardiovascular events risk. • Aspirin does not reduce all-cause mortality risk. • Aspirin does increase the risk of major bleeding risk. • Aspirin prescription in primary prevention in diabetics must be individualized. |
|---|---|
| Beschreibung: | 9 |
| DOI: | 10.1016/j.pcd.2019.11.004 |